dual glp-1/gip receptor agonists This review summarizes how GLP-1 and GIP/GLP-1 act at the cellular level and their therapeutic applications in metabolic diseases like type 2 diabetes and obesity, highlighting advances in incretin-based The mechanisms of dual incretin

Description

Other, rare side effects associated with taking these drugs include gallstones, pancreatitis, and more severe gastrointestinal problems, such as bowel obstruction or gastroparesis (in which the muscles in the stomach are partially paralyzed and dont move properly for digestion)

Chung MC, Hung PH, Hsiao PJ, Wu LY, Chang CH, Wu MJ, Shieh JJ, Chung CJ

Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management

Emerging research suggests GLP-1 receptor agonists may reduce inflammatory markers such as C-reactive protein and pro-inflammatory cytokines, though dedicated clinical trials examining low-dose regimens specifically for inflammation are lacking